SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention after its CEOs anniversary message prompted renewed speculation about a potential buyout, alongside anticipation for the final analysis of its Phase 3 REGAL leukemia trial, which requires 80 events and was last reported at 78. Traders disagree on whether the message and prolonged trial timeline signal favorable data or a deal; neither a buyout nor a trial outcome has been confirmed.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rises amid reported Middle East shipping and energy-infrastructure attacks, fueling concerns about oil-supply disruptions. Traders are divided over whether geopolitical risks will keep prices elevated or whether Iran-US deal headlines and Russian supply relief will unwind the risk premium; some also question the reliability of the headlines.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff is drawing attention amid HSBCs bearish assessment and concerns about heavy debt, borrowing costs and access to financing for its AI infrastructure expansion. Traders are divided between expecting further downside and betting on a rebound or short squeeze; some bulls point to reported GPU price increases as evidence of demand and pricing power.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a sharp selloff and weak performance versus peers as traders debate neocloud financing risks and broader concerns about AI infrastructure spending. The co-CEOs statement that data centers carry no debt and customer prepayments help fund GPU costs has reassured some investors, while others remain concerned about execution and the stocks continued weakness.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins rebound from recent lows and its struggle to clear near-term resistance are driving discussion, with traders debating whether the move can extend or fade into another pullback. Bulls see potential for a short squeeze, while skeptics call the bounce a trap and point to weak demand and macro uncertainty.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is drawing attention for persistent share-price underperformance and widespread frustration with managements shift toward external acquisitions and pipeline investment, which critics fear could add debt and dilution. Bulls point to Orladeyos revenue and upcoming Netherton and Navenibart data, while bearish traders question whether those prospects can restore confidence.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows has focused discussion on waning confidence in Trump ahead of the midterms and concerns about Truth Socials engagement and the companys underlying business. Bearish traders see room for further declines, while some view the selloff as an opportunity for a short-term bounce.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians improved Q3 outlook and reaffirmed 2026 forecast, alongside Carnivals strong results and raised guidance, have lifted cruise-sector sentiment and sparked a move in NCLH. Traders are optimistic about a catch-up rally and possible short covering, while some remain cautious about NCLH lagging peers and ongoing fuel-cost and management concerns.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Unconfirmed reports of a possible US-Iran dealand a pullback in oil pricesare widely cited as drivers of QQQs sharp rebound and volatile swings. Traders disagree over whether the rally is durable or a headline-driven bull trap, while upcoming big-tech earnings and AI-sector weakness add uncertainty.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas plans to pursue a public listing for financial-services arm Monee and launch an AI enterprise platform are drawing attention, but traders are divided over whether the separation could unlock value or leave SE with less attractive businesses; some also question whether existing shareholders would receive Monee shares. The discussion is amplified by SEs sharp selloff and concerns about insider sales and managements lack of buybacks, though traders disagree on what is driving the decline.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug

Equity

Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia.

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 14.04% on an annualized basis producing an average annual return of 27.55%. Currently, Ascendis Pharma has a market capitalization ofread more...

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 16.08% on an annualized basis producing an average annual return of 29.64%. Currently, Ascendis Pharma has a market capitalization ofread more...

Insider Decision: Mads Bodenhoff Offloads $810K Worth Of Ascendis Pharma Stock

Mads Bodenhoff, SVP & PAO at Ascendis Pharma (NASDAQ:ASND), reported an insider sell on September 9, according to a new SEC filing.
What Happened: Bodenhoff's decision to sell 3,000 shares of Ascendis Pharmaread more...

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

BMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.

ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged

BioMarin and Ascendis settled a global patent dispute over the achondroplasia drug Yuviwel on Sunday. 

Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday.

On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)read more...

FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo

BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.

• Reported GAAP EPS of $3.22 up 603.12% YoY
• Reported revenue of $339.29M up 114.68% YoY

Ascendis Pharma faces material risks from regulatory review timelines for YUVIWEL, potential reimbursement and pricing challenges for its product portfolio, and dependencies on third-party manufacturing and logistics for commercial operations.

Ascendis Pharma delivered strong 105% year-over-year product revenue growth in Q2 2026 and achieved profitability, supported by robust demand for its TransCon commercial products and continued advancement of its clinical pipeline.

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

Neutral Sentiment

<ul class="summary-bullets"><li>Final European Commission authorization is still pending, with a decision expected in the fourth quarter of 2026 and a potential first launch in Germany in the first quarter of 2027.</li><li>Ascendis has three approved commercial products.</li><li>TransCon CNP, marketed as YUVIWEL in the U.S., received FDA approval in February 2026.</li></ul>Ascendis Pharma (ASND) said on Friday that it has received a positive European regulatory opinion for its once-weekly treatment for children with achondroplasia.Shares of the company closed down 0.6%, as investors likely viewed the positive opinion as expected, provided it is already approved in the U.S. TransCon CNP, marketed as YUVIWEL in the U.S., received FDA approval in February 2026 to increase linear growth in children two years and older with open growth plates.<h2 class="st-heading-2">CHMP Opinion On Ascendis Drug</h2>Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia for children two years of age and older whose epiphyses, or the expanded end of a long bone, are not closed. The opinion followed review of data from three randomized, double-blind, placebo-controlled trials plus up to three years of open-label extension results, including the pivotal ApproaCH trial. Final European Commission authorization is still pending, with a decision expected in the fourth quarter of 2026 and a potential first launch in Germany in the first quarter of 2027.Chief Executive Officer Jan Mikkelsen said the positive opinion reflects the unique profile of TransCon CNP and that the therapy remains a foundational product in the company’s growth disorder portfolio supporting its longer-term objectives.Ascendis has three approved commercial products, including TransCon CNP. In the second quarter, or its first quarter of commercial sales, the drug recorded €7.6–8 million in revenue, accounting for a small portion of the company’s overall product revenue of €315 million. YORVIPATH accounts for a lion’s share of the company’s overall sales.<h2 class="st-heading-2">How Did ASND Retail Traders React?</h2>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/ASND">ASND stock</a>&nbsp;stayed within bearish territory over the past 24 hours, while message volume stayed within normal levels.ASND stock has gained 6% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omeros-shares-slide-after-chmp-upholds-negative-opinion-on-drug-analyst-sees-buying-opportunity-at-16/cZxKQ9ERBtG">Omeros Shares Slide After CHMP Upholds Negative Opinion On Drug; Analyst Sees Buying Opportunity At $16</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ascendis Pharma logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Ascendis Pharma

iShares Biotechnology ETF

T Rowe Price Capital Appreciation Equity ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Stocktwits Polls

$ASND 

Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia.

Mike

ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug

$ASND $TCAF $IBB

https://stocktwits.com/news/equity/markets/asnd-shares-shrug-off-positive-european-opinion-for-fda-approved-achondroplasia-drug/cZxKWRBRBtT

Stocktwits News

$ASND Copenhagen biopharma Ascendis Pharma plans to launch its weekly achondroplasia drug TransCon CNP (YUVIWEL) in Germany in Q1 2027 if the EU approves it, after the EMA's CHMP backed approval for children 2 and older. The drug has been FDA-approved since Feb 2026; Ascendis was valued at about $14.05B at $226.62 at 16:00 ET Oct 15, 2026. The other side: EMA will now review whether it keeps its orphan designation, and a CHMP opinion is not approval. The European Commission's final decision is expected in Q4 2026.

Filecrux

$ASND three wave corrective-looking pullback from the July high may be complete at the Fib .786 retracement level, with bullish divergences on the technical indicators

Feed

News

Sentiment

Earnings

Fundamentals

Info

ASND Ascendis Pharma

Fundamentals

Latest ASND News